| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyBiologicalProcess | positive regulation of natural killer cell mediated cytotoxicity | 5.47e-05 | 40 | 6 | 2 | GO:0045954 | |
| GeneOntologyBiologicalProcess | positive regulation of natural killer cell mediated immunity | 6.64e-05 | 44 | 6 | 2 | GO:0002717 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated cytotoxicity | 1.99e-04 | 76 | 6 | 2 | GO:0042269 | |
| GeneOntologyBiologicalProcess | positive regulation of leukocyte mediated cytotoxicity | 2.15e-04 | 79 | 6 | 2 | GO:0001912 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated immunity | 2.21e-04 | 80 | 6 | 2 | GO:0002715 | |
| GeneOntologyBiologicalProcess | positive regulation of cell killing | 2.67e-04 | 88 | 6 | 2 | GO:0031343 | |
| GeneOntologyBiologicalProcess | positive regulation of B cell activation | 3.45e-04 | 100 | 6 | 2 | GO:0050871 | |
| GeneOntologyBiologicalProcess | lymphocyte homeostasis | 3.73e-04 | 104 | 6 | 2 | GO:0002260 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated cytotoxicity | 3.80e-04 | 105 | 6 | 2 | GO:0042267 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated immunity | 4.09e-04 | 109 | 6 | 2 | GO:0002228 | |
| GeneOntologyBiologicalProcess | regulation of leukocyte mediated cytotoxicity | 5.29e-04 | 124 | 6 | 2 | GO:0001910 | |
| GeneOntologyBiologicalProcess | natural killer cell activation | 5.29e-04 | 124 | 6 | 2 | GO:0030101 | |
| GeneOntologyBiologicalProcess | positive regulation of T cell proliferation | 5.38e-04 | 125 | 6 | 2 | GO:0042102 | |
| GeneOntologyBiologicalProcess | regulation of cell killing | 7.43e-04 | 147 | 6 | 2 | GO:0031341 | |
| GeneOntologyBiologicalProcess | positive regulation of lymphocyte mediated immunity | 7.73e-04 | 150 | 6 | 2 | GO:0002708 | |
| GeneOntologyBiologicalProcess | leukocyte homeostasis | 8.04e-04 | 153 | 6 | 2 | GO:0001776 | |
| GeneOntologyBiologicalProcess | regulation of B cell activation | 9.12e-04 | 163 | 6 | 2 | GO:0050864 | |
| GeneOntologyBiologicalProcess | positive regulation of lymphocyte proliferation | 9.91e-04 | 170 | 6 | 2 | GO:0050671 | |
| GeneOntologyBiologicalProcess | positive regulation of mononuclear cell proliferation | 1.03e-03 | 173 | 6 | 2 | GO:0032946 | |
| GeneOntologyBiologicalProcess | positive regulation of leukocyte mediated immunity | 1.05e-03 | 175 | 6 | 2 | GO:0002705 | |
| GeneOntologyBiologicalProcess | leukocyte mediated cytotoxicity | 1.20e-03 | 187 | 6 | 2 | GO:0001909 | |
| GeneOntologyBiologicalProcess | positive regulation of leukocyte proliferation | 1.25e-03 | 191 | 6 | 2 | GO:0070665 | |
| GeneOntologyBiologicalProcess | positive regulation of immune response | 1.25e-03 | 845 | 6 | 3 | GO:0050778 | |
| GeneOntologyBiologicalProcess | B cell differentiation | 1.38e-03 | 201 | 6 | 2 | GO:0030183 | |
| GeneOntologyBiologicalProcess | regulation of lymphocyte mediated immunity | 1.83e-03 | 232 | 6 | 2 | GO:0002706 | |
| GeneOntologyBiologicalProcess | lymphocyte activation | 1.90e-03 | 976 | 6 | 3 | GO:0046649 | |
| GeneOntologyBiologicalProcess | regulation of T cell proliferation | 1.90e-03 | 236 | 6 | 2 | GO:0042129 | |
| GeneOntologyBiologicalProcess | regulation of immune response | 2.57e-03 | 1085 | 6 | 3 | GO:0050776 | |
| GeneOntologyBiologicalProcess | T cell proliferation | 2.81e-03 | 288 | 6 | 2 | GO:0042098 | |
| GeneOntologyBiologicalProcess | positive regulation of T cell activation | 2.85e-03 | 290 | 6 | 2 | GO:0050870 | |
| GeneOntologyBiologicalProcess | regulation of lymphocyte proliferation | 3.06e-03 | 301 | 6 | 2 | GO:0050670 | |
| GeneOntologyBiologicalProcess | regulation of mononuclear cell proliferation | 3.16e-03 | 306 | 6 | 2 | GO:0032944 | |
| GeneOntologyBiologicalProcess | cell killing | 3.18e-03 | 307 | 6 | 2 | GO:0001906 | |
| GeneOntologyBiologicalProcess | regulation of leukocyte mediated immunity | 3.22e-03 | 309 | 6 | 2 | GO:0002703 | |
| GeneOntologyBiologicalProcess | leukocyte activation | 3.33e-03 | 1186 | 6 | 3 | GO:0045321 | |
| GeneOntologyBiologicalProcess | positive regulation of immune effector process | 3.39e-03 | 317 | 6 | 2 | GO:0002699 | |
| GeneOntologyBiologicalProcess | positive regulation of leukocyte cell-cell adhesion | 3.39e-03 | 317 | 6 | 2 | GO:1903039 | |
| GeneOntologyBiologicalProcess | regulation of leukocyte proliferation | 3.71e-03 | 332 | 6 | 2 | GO:0070663 | |
| GeneOntologyBiologicalProcess | positive regulation of immune system process | 3.80e-03 | 1242 | 6 | 3 | GO:0002684 | |
| GeneOntologyBiologicalProcess | B cell activation | 3.91e-03 | 341 | 6 | 2 | GO:0042113 | |
| GeneOntologyBiologicalProcess | cell activation | 4.88e-03 | 1356 | 6 | 3 | GO:0001775 | |
| Pathway | PID_ERA_GENOMIC_PATHWAY | 4.20e-04 | 64 | 7 | 2 | M200 | |
| Pathway | WP_EXTRAFOLLICULAR_AND_FOLLICULAR_B_CELL_ACTIVATION_BY_SARSCOV2 | 5.61e-04 | 74 | 7 | 2 | M45517 | |
| Pubmed | Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia. | 1.04e-07 | 3 | 7 | 2 | 29235481 | |
| Pubmed | Adaptor proteins NUMB and NUMBL promote cell cycle withdrawal by targeting ERBB2 for degradation. | 5.93e-06 | 19 | 7 | 2 | 28067668 | |
| Interaction | EPAS1 interactions | 2.12e-05 | 173 | 7 | 3 | int:EPAS1 | |
| GeneFamily | ADAM metallopeptidase domain containing|CD molecules | 4.54e-03 | 394 | 5 | 2 | 471 | |
| Coexpression | SHIN_B_CELL_LYMPHOMA_CLUSTER_2 | 2.83e-05 | 31 | 7 | 2 | M1384 | |
| Coexpression | SHIN_B_CELL_LYMPHOMA_CLUSTER_2 | 3.02e-05 | 32 | 7 | 2 | MM585 | |
| Coexpression | FIGUEROA_AML_METHYLATION_CLUSTER_4_UP | 3.75e-04 | 112 | 7 | 2 | M2170 | |
| Coexpression | TABULA_MURIS_SENIS_HEART_VENTRICULAR_MYOCYTE_AGEING | 4.30e-04 | 120 | 7 | 2 | MM3710 | |
| Coexpression | GSE7219_UNSTIM_VS_LPS_AND_ANTI_CD40_STIM_DC_DN | 9.00e-04 | 174 | 7 | 2 | M381 | |
| Coexpression | GSE37532_WT_VS_PPARG_KO_LN_TREG_UP | 9.21e-04 | 176 | 7 | 2 | M8952 | |
| Coexpression | GSE29617_DAY3_VS_DAY7_TIV_FLU_VACCINE_PBMC_2008_UP | 1.06e-03 | 189 | 7 | 2 | M4933 | |
| Coexpression | GSE27241_CTRL_VS_DIGOXIN_TREATED_CD4_TCELL_IN_TH17_POLARIZING_CONDITIONS_DN | 1.15e-03 | 197 | 7 | 2 | M8227 | |
| Coexpression | GSE22611_UNSTIM_VS_6H_MDP_STIM_MUTANT_NOD2_TRANSDUCED_HEK293T_CELL_UP | 1.16e-03 | 198 | 7 | 2 | M8162 | |
| Coexpression | GSE5542_IFNA_VS_IFNA_AND_IFNG_TREATED_EPITHELIAL_CELLS_6H_DN | 1.17e-03 | 199 | 7 | 2 | M6538 | |
| Coexpression | GSE30971_CTRL_VS_LPS_STIM_MACROPHAGE_WBP7_HET_2H_DN | 1.17e-03 | 199 | 7 | 2 | M8709 | |
| Coexpression | GSE22196_HEALTHY_VS_OBESE_MOUSE_SKIN_GAMMADELTA_TCELL_UP | 1.17e-03 | 199 | 7 | 2 | M7655 | |
| Coexpression | GSE14350_IL2RB_KO_VS_WT_TREG_UP | 1.17e-03 | 199 | 7 | 2 | M3421 | |
| Coexpression | GSE20366_TREG_VS_NAIVE_CD4_TCELL_HOMEOSTATIC_CONVERSION_DN | 1.17e-03 | 199 | 7 | 2 | M4331 | |
| Coexpression | GSE36078_UNTREATED_VS_AD5_INF_MOUSE_LUNG_DC_UP | 1.19e-03 | 200 | 7 | 2 | M9289 | |
| Coexpression | GSE40666_NAIVE_VS_EFFECTOR_CD8_TCELL_UP | 1.19e-03 | 200 | 7 | 2 | M9203 | |
| Coexpression | GSE32986_UNSTIM_VS_CURDLAN_HIGHDOSE_STIM_DC_DN | 1.19e-03 | 200 | 7 | 2 | M8618 | |
| Coexpression | GSE40277_EOS_AND_LEF1_TRANSDUCED_VS_CTRL_CD4_TCELL_UP | 1.19e-03 | 200 | 7 | 2 | M9171 | |
| Coexpression | GSE22601_IMMATURE_CD4_SINGLE_POSITIVE_VS_DOUBLE_POSITIVE_THYMOCYTE_DN | 1.19e-03 | 200 | 7 | 2 | M6247 | |
| Coexpression | GSE2585_CTEC_VS_THYMIC_MACROPHAGE_UP | 1.19e-03 | 200 | 7 | 2 | M6268 | |
| Coexpression | GSE19401_UNSTIM_VS_RETINOIC_ACID_AND_PAM2CSK4_STIM_FOLLICULAR_DC_UP | 1.19e-03 | 200 | 7 | 2 | M7665 | |
| Coexpression | GSE5503_LIVER_DC_VS_SPLEEN_DC_ACTIVATED_ALLOGENIC_TCELL_UP | 1.19e-03 | 200 | 7 | 2 | M6996 | |
| ToppCell | TCGA-Bone_and_Soft_Tissue-Primary_Tumor-Sarcoma-Dedifferentiated_Liposarcoma-3|TCGA-Bone_and_Soft_Tissue / Sample_Type by Project: Shred V9 | 1.21e-04 | 109 | 7 | 2 | 5d194bf95eb777fb4d01bbe5b1639f17ea1bc11a | |
| ToppCell | 343B-Lymphocytic-NK_cells-NK_cell_A2|343B / Donor, Lineage, Cell class and subclass (all cells) | 1.80e-04 | 133 | 7 | 2 | 8ff1cf0ea1fc33fe8384c0e65c1ee1853b25a2ae | |
| ToppCell | facs-Brain_Myeloid-Cerebellum_-18m-Myeloid|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.64e-04 | 161 | 7 | 2 | c5d9d47dcedfbb1ac77f4afaf860ae4d9f26fd3f | |
| ToppCell | facs-Brain_Myeloid-Cerebellum_-18m|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.64e-04 | 161 | 7 | 2 | b14a83ad07a7acb07c766aa862b527698976b6fc | |
| ToppCell | facs-Brain_Myeloid-Cerebellum_|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.64e-04 | 161 | 7 | 2 | 5c762609531a7c5505aa5637abf8e0311568d7fd | |
| ToppCell | facs-Brain_Myeloid-Cerebellum_-18m-Myeloid-nan|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.64e-04 | 161 | 7 | 2 | 26c0d876339bfd34d9a43af5b9fb08f50526f2c9 | |
| ToppCell | TCGA-Ovary-Primary_Tumor-Ovarian_Carcinoma-Serous_Cystadenocarcinoma-1|TCGA-Ovary / Sample_Type by Project: Shred V9 | 2.77e-04 | 165 | 7 | 2 | 2ca1154a8692af311d99a4d3aa2f2ac3d23a4310 | |
| ToppCell | facs-Brain_Myeloid-Cerebellum_-18m-Myeloid-microglial_cell|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.81e-04 | 166 | 7 | 2 | 4ab1959c526c2fd83077fc03e4de207f34841a19 | |
| ToppCell | droplet-Thymus-nan-24m-Lymphocytic-double_negative_T_cell|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.88e-04 | 168 | 7 | 2 | de1042267407719f19eb3f580a5df0c9cd0e8273 | |
| ToppCell | droplet-Lung-immune-endo-depleted-3m-Myeloid-Myeloid_Dendritic_Type_2|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.12e-04 | 175 | 7 | 2 | bb058e714d21a0ec8532eaf3c7dd2faf78016bc0 | |
| ToppCell | 3'-Distal_airway-Immune_Myeloid-Myeloid_macrophage-alveolar_macrophage-Alveolar_macrophages-Alveolar_macrophages_L.1.0.3.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 3.15e-04 | 176 | 7 | 2 | 76fdf211bce101e83a27d822cb399487bd107027 | |
| ToppCell | 3'-Pediatric_IBD-SmallIntestine-Hematopoietic-Myeloid-MMP9+_Inflammatory_macrophage|Pediatric_IBD / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 3.87e-04 | 195 | 7 | 2 | 5a7c74f96f213c504abd65e751800da7e03e47d9 | |
| ToppCell | CV-Mild-0|Mild / Virus stimulation, Condition and Cluster | 3.87e-04 | 195 | 7 | 2 | 2ffb9a9b6143bb404fe454cd939b573252bba6e9 | |
| ToppCell | LPS_anti-TNF|World / Treatment groups by lineage, cell group, cell type | 3.95e-04 | 197 | 7 | 2 | 7768e613fa48a6ec4a3902559310b51345a7fe91 | |
| ToppCell | renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell-Degenerative_Outer_Medullary_Collecting_Duct_Principal_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 3.99e-04 | 198 | 7 | 2 | 0d9d401190792fd61434f1b82548253187d805f0 | |
| Drug | fenarimol | 1.37e-04 | 59 | 7 | 2 | CID000043226 | |
| Drug | AC1L1BB2 | 2.72e-04 | 83 | 7 | 2 | CID000001361 | |
| Drug | Prestwick_517 | 4.44e-04 | 106 | 7 | 2 | CID000003804 | |
| Drug | NSC145391 | 9.95e-04 | 159 | 7 | 2 | CID000286683 | |
| Drug | wortmannin from Penicillium funiculosum; Up 200; 0.01uM; MCF7; HT_HG-U133A_EA | 1.33e-03 | 184 | 7 | 2 | 1081_UP | |
| Drug | LY 294002; Up 200; 10uM; MCF7; HT_HG-U133A | 1.37e-03 | 187 | 7 | 2 | 5233_UP | |
| Drug | wortmannin; Up 200; 0.01uM; MCF7; HT_HG-U133A_EA | 1.40e-03 | 189 | 7 | 2 | 911_UP | |
| Drug | radicicol, diheterospora chlamydosporia; Up 200; 0.1uM; MCF7; HT_HG-U133A | 1.42e-03 | 190 | 7 | 2 | 6979_UP | |
| Drug | Pyrimethamine [58-14-0]; Down 200; 16uM; HL60; HG-U133A | 1.42e-03 | 190 | 7 | 2 | 1974_DN | |
| Drug | Bacampicillin hydrochloride [37661-08-8]; Up 200; 8uM; HL60; HT_HG-U133A | 1.44e-03 | 192 | 7 | 2 | 1337_UP | |
| Drug | pioglitazone HCl; Up 200; 10uM; MCF7; HT_HG-U133A | 1.44e-03 | 192 | 7 | 2 | 6898_UP | |
| Drug | Meclocycline sulfosalicylate [73816-42-9]; Up 200; 5.8uM; HL60; HT_HG-U133A | 1.46e-03 | 193 | 7 | 2 | 1341_UP | |
| Drug | Iopanoic acid [96-83-3]; Down 200; 7uM; MCF7; HT_HG-U133A | 1.47e-03 | 194 | 7 | 2 | 3527_DN | |
| Drug | (R) -Naproxen sodium salt [26159-34-2]; Down 200; 15.8uM; MCF7; HT_HG-U133A | 1.47e-03 | 194 | 7 | 2 | 6794_DN | |
| Drug | Dirithromycin [62013-04-1]; Down 200; 4.8uM; MCF7; HT_HG-U133A | 1.47e-03 | 194 | 7 | 2 | 2863_DN | |
| Drug | AG-028671 [847803-03-6]; Up 200; 10uM; PC3; HT_HG-U133A | 1.49e-03 | 195 | 7 | 2 | 6557_UP | |
| Drug | Acenocoumarol [152-72-7]; Up 200; 11.4uM; PC3; HT_HG-U133A | 1.49e-03 | 195 | 7 | 2 | 5878_UP | |
| Drug | Guanethidine sulfate [60-02-6]; Up 200; 13.4uM; MCF7; HT_HG-U133A | 1.50e-03 | 196 | 7 | 2 | 3171_UP | |
| Drug | Retrorsine [480-54-6]; Up 200; 11.4uM; MCF7; HT_HG-U133A | 1.50e-03 | 196 | 7 | 2 | 2784_UP | |
| Drug | Pregnenolone [145-13-1]; Down 200; 12.6uM; MCF7; HT_HG-U133A | 1.50e-03 | 196 | 7 | 2 | 4802_DN | |
| Drug | Nifedipine [21829-25-4]; Up 200; 11.6uM; HL60; HT_HG-U133A | 1.50e-03 | 196 | 7 | 2 | 1856_UP | |
| Drug | Methoxy-8-psoralen [298-81-7]; Down 200; 18.6uM; MCF7; HT_HG-U133A | 1.50e-03 | 196 | 7 | 2 | 5007_DN | |
| Drug | 16, 16-dimethylprostaglandin E2 methyl acetate solution; Down 200; 10uM; PC3; HT_HG-U133A | 1.50e-03 | 196 | 7 | 2 | 6562_DN | |
| Drug | (-)-depudecin; Down 200; 1uM; MCF7; HT_HG-U133A_EA | 1.50e-03 | 196 | 7 | 2 | 982_DN | |
| Drug | 5255229; Up 200; 13uM; MCF7; HT_HG-U133A_EA | 1.50e-03 | 196 | 7 | 2 | 833_UP | |
| Drug | Amphotericin B [1397-89-3]; Down 200; 4.4uM; MCF7; HT_HG-U133A | 1.50e-03 | 196 | 7 | 2 | 5404_DN | |
| Drug | Phenazopyridine hydrochloride [136-40-3]; Down 200; 16uM; HL60; HT_HG-U133A | 1.50e-03 | 196 | 7 | 2 | 2537_DN | |
| Drug | Graveoline [485-61-0]; Down 200; 14.4uM; HL60; HT_HG-U133A | 1.50e-03 | 196 | 7 | 2 | 2179_DN | |
| Drug | Fluvoxamine maleate [61718-82-9]; Up 200; 9.2uM; MCF7; HT_HG-U133A | 1.50e-03 | 196 | 7 | 2 | 7333_UP | |
| Drug | Mefenamic acid [61-68-7]; Down 200; 16.6uM; PC3; HT_HG-U133A | 1.50e-03 | 196 | 7 | 2 | 1821_DN | |
| Drug | Netilmicin sulfate [56931-57-2]; Down 200; 2.8uM; HL60; HT_HG-U133A | 1.50e-03 | 196 | 7 | 2 | 2963_DN | |
| Drug | Homatropine hydrobromide (R,S) [51-56-9]; Down 200; 11.2uM; PC3; HT_HG-U133A | 1.52e-03 | 197 | 7 | 2 | 1806_DN | |
| Drug | Trimetazidine dihydrochloride [13171-25-0]; Down 200; 11.8uM; MCF7; HT_HG-U133A | 1.52e-03 | 197 | 7 | 2 | 5479_DN | |
| Drug | Conessine [546-06-5]; Up 200; 11.2uM; MCF7; HT_HG-U133A | 1.52e-03 | 197 | 7 | 2 | 2792_UP | |
| Drug | Myricetin [529-44-2]; Down 200; 12.6uM; MCF7; HT_HG-U133A | 1.52e-03 | 197 | 7 | 2 | 3270_DN | |
| Drug | Cefuroxime sodium salt [56238-63-2]; Down 200; 9uM; HL60; HT_HG-U133A | 1.52e-03 | 197 | 7 | 2 | 2526_DN | |
| Drug | Levopropoxyphene napsylate [5714-90-9]; Down 200; 7.4uM; MCF7; HT_HG-U133A | 1.52e-03 | 197 | 7 | 2 | 5503_DN | |
| Drug | Vancomycin hydrochloride [1404-93-9]; Down 200; 2.6uM; HL60; HT_HG-U133A | 1.52e-03 | 197 | 7 | 2 | 2498_DN | |
| Drug | Picotamide monohydrate [80530-63-8]; Down 200; 10.2uM; MCF7; HT_HG-U133A | 1.52e-03 | 197 | 7 | 2 | 6787_DN | |
| Drug | Etofylline [519-37-9]; Down 200; 17.8uM; PC3; HT_HG-U133A | 1.52e-03 | 197 | 7 | 2 | 2093_DN | |
| Drug | Gliquidone [33342-05-1]; Down 200; 7.6uM; HL60; HT_HG-U133A | 1.52e-03 | 197 | 7 | 2 | 3126_DN | |
| Drug | Phenylpropanolamine hydrochloride [154-41-6]; Down 200; 21.4uM; HL60; HG-U133A | 1.52e-03 | 197 | 7 | 2 | 1602_DN | |
| Drug | Asiaticoside [16830-15-2]; Down 200; 4.2uM; HL60; HT_HG-U133A | 1.54e-03 | 198 | 7 | 2 | 2943_DN | |
| Drug | L(-)-vesamicol hydrochloride [112709-59-8]; Down 200; 13.6uM; MCF7; HT_HG-U133A | 1.54e-03 | 198 | 7 | 2 | 6497_DN | |
| Drug | clotrimazole; Down 200; 50uM; MCF7; HT_HG-U133A_EA | 1.54e-03 | 198 | 7 | 2 | 905_DN | |
| Drug | Trolox [53188-07-1]; Down 200; 16uM; PC3; HT_HG-U133A | 1.54e-03 | 198 | 7 | 2 | 7304_DN | |
| Drug | Amikacin hydrate [37517-28-5]; Down 200; 6.6uM; MCF7; HT_HG-U133A | 1.54e-03 | 198 | 7 | 2 | 5314_DN | |
| Drug | Riluzole hydrochloride; Up 200; 14.8uM; MCF7; HT_HG-U133A | 1.54e-03 | 198 | 7 | 2 | 4689_UP | |
| Drug | Mesalamine [89-57-6]; Down 200; 26.2uM; PC3; HT_HG-U133A | 1.55e-03 | 199 | 7 | 2 | 5888_DN | |
| Drug | Prednisone [53-03-2]; Down 200; 11.2uM; PC3; HG-U133A | 1.55e-03 | 199 | 7 | 2 | 1897_DN | |
| Drug | 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane | 1.66e-03 | 206 | 7 | 2 | ctd:C404910 | |
| Disease | urate measurement, bone density | 8.60e-03 | 619 | 7 | 2 | EFO_0003923, EFO_0004531 | |
| Disease | monocyte percentage of leukocytes | 1.18e-02 | 731 | 7 | 2 | EFO_0007989 | |
| Disease | Malignant neoplasm of breast | 2.46e-02 | 1074 | 7 | 2 | C0006142 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| NVSRLEGDDNPVQLI | 1226 | Q9HCM3 | |
| ILVQGQEVTRPIIDF | 191 | Q5T1V6 | |
| LQGIQLNTILPDARD | 301 | P11279 | |
| DTLGQAQQRVAELEP | 326 | Q9P1Z2 | |
| PQDRAQATQLLEGLV | 51 | P42229 | |
| EDNRSLGVIPQDEQL | 1691 | Q8NFU7 | |
| GDELQLAIPRENAQI | 256 | Q9Y275 |